NEUP

Neuphoria Therapeutics Inc

• Reuters·02/17 20:58

  Neuphoria Therapeutics posts Q4 income before income taxes of USD 1.83 million, reversing a loss

• TipRanks·01/08 11:32

  Neuphoria Therapeutics Announces CEO Transition and Consulting Role

• Reuters·12/29/2025 21:40

  LYNX1 CAPITAL MANAGEMENT - ON DEC 26, OFFERED TO ACQUIRE NEUPHORIA THERAPEUTICS' IP ASSETS VIA CASH OR EQUIVALENT STOCK - SEC FILING

• TipRanks·12/17/2025 21:39

  Neuphoria Therapeutics Shareholders Align on Key Proposals

• TipRanks·12/08/2025 13:05

  Neuphoria announces ISS recommends shareholders vote ‘FOR’ director nominees

• Dow Jones·12/08/2025 13:00

  Press Release: Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees

• Dow Jones·12/05/2025 13:05

  Neuphoria Therapeutics Is Maintained at Buy by HC Wainwright & Co.

• Dow Jones·12/05/2025 13:05

  Neuphoria Therapeutics Price Target Cut to $7.00/Share From $21.00 by HC Wainwright & Co.

• Benzinga·12/05/2025 12:55

  HC Wainwright & Co. Maintains Buy on Neuphoria Therapeutics, Lowers Price Target to $7

• TipRanks·12/05/2025 12:50

  Analysts Are Bullish on Top Healthcare Stocks: Adicet Bio (ACET), Palvella Therapeutics (PVLA)

• TipRanks·12/05/2025 12:45

  Neuphoria Therapeutics price target lowered to $7 from $21 at H.C. Wainwright

• Reuters·12/05/2025 12:34

  NEUPHORIA THERAPEUTICS INC. <NEUP.O>: H.C. WAINWRIGHT CUTS TARGET PRICE TO $7 FROM $21

• TipRanks·12/04/2025 13:10

  Neuphoria Therapeutics responds to Lynx1’s revised indication of interest

• Reuters·12/04/2025 13:00

  NEUPHORIA RESPONDS TO LYNX1’S REVISED INDICATION OF INTEREST AT A REDUCED PRICE AND PREMIUM

• Reuters·12/04/2025 13:00

  NEUPHORIA THERAPEUTICS INC - PAUSES R&D EXPENDITURES FOR BNC210 IN PTSD & IS EVALUATING ALL POSSIBILITIES AS PART OF THE CO'S STRATEGIC REVIEW